Silvercrest Asset Management Group 13F: Cuts ICUI Stake by $8.4M

Silvercrest Asset Management Group has reduced its position in ICU Medical, Inc. (NASDAQ: ICUI) by 14.9%, according to its latest 13F filing with the SEC. The firm sold 56,787 shares, bringing its total holdings to 323,676 shares, valued at approximately $47.88 million.

What Changed in Silvercrest's ICU Medical Position

Silvercrest Asset Management trimmed its stake in ICU Medical by selling 56,787 shares, reducing its holdings by 14.9% to 323,676 shares. The value of its position now stands at about $47.88 million. This adjustment was reported in the firm's latest quarterly filing.

Other Institutional Activity in ICU Medical

Among other institutional investors, BlackRock, Inc. increased its holdings by 20,167 shares, ending with 3,608,322 shares valued at roughly $466.01 million. Janus Henderson Group PLC added 99,256 shares, now holding 2,676,012 shares worth about $345.61 million, marking a 3.9% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, each holding 1,437,676 and 1,111,875 shares valued at $185.68 million and $143.60 million, respectively. Conversely, Fuller & Thaler Asset Management, Inc. reduced its stake by 45,260 shares, now holding 1,220,539 shares valued at approximately $157.63 million.

ICU Medical, Inc. Stock Down 3.1%

On Tuesday, shares of ICU Medical traded near $147.93. The company, with a market cap of about $3.71 billion, has a P/E ratio of 80.15 and a forward P/E of 15.94. Its beta is 0.778, indicating lower volatility than the market. The stock's 52-week range is between $107.00 and $160.29, with a 50-day moving average of $130.76 and a 200-day moving average of $135.24. ICU Medical's current ratio is 2.34, and its quick ratio is 0.95, with a debt-to-equity ratio of 63.62.

Recent Earnings

ICU Medical reported revenues of approximately $2.16 billion with a slight decline of 12.3% in revenue growth. The company's earnings per share (EPS) is $1.85, with a net margin of 2.15% and a return on equity (ROE) of 2.26%. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at ICU Medical, Inc.

Recent insider activity at ICU Medical includes sales by President Daniel Woolson, who sold 2,123 shares on May 22, 2026, at an average price of $132.21. Virginia Ruth Sanzone, VP and General Counsel, sold 2,447 shares on May 14, 2026, at $124.08. On May 13, 2026, insiders David Greenberg, David Hoffmeister, and Elisha Finney each bought 1,254 shares, though the transaction price was not disclosed.

Analysts Set New Price Targets

On June 15, 2026, BTIG initiated coverage on ICU Medical with a "buy" rating and a $170 price target. Needham upgraded the stock to "buy" with a $165 target on May 27, 2026. Other firms like Keybanc and Piper Sandler maintained their "buy" ratings, setting targets between $163 and $180. The consensus among analysts is a strong buy, with a mean target price of $172.50 based on eight opinions.

About ICU Medical

ICU Medical, Inc., headquartered in San Clemente, California, specializes in developing and selling medical products for infusion therapy, vascular access, and vital care. The company offers a range of products, including infusion pumps, catheter devices, and IV therapy solutions, serving customers like hospitals and home health care providers worldwide. It was founded in 1984 and is led by CEO Mr. Vivek Jain, employing around 13,000 people.

Bottom Line

Silvercrest Asset Management's reduction in ICU Medical holdings reflects a notable shift in its investment strategy. Investors keep a close eye on these filings for insights into institutional sentiment. While 13F filings are backward-looking, they offer a snapshot of fund activity and potential trends in the stock market.